Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $127000.0.

  • Viridian Therapeutics, Inc.\DE's Capital Expenditures fell 5665.53% to $127000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $369000.0, marking a year-over-year decrease of 1707.87%. This contributed to the annual value of $511000.0 for FY2024, which is 4309.58% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Capital Expenditures of $127000.0 as of Q3 2025, which was down 5665.53% from $42000.0 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Capital Expenditures ranged from a high of $404000.0 in Q3 2023 and a low of $15000.0 during Q1 2021
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Capital Expenditures had a median value of $120500.0 in 2024 and averaged $155500.0.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Capital Expenditures soared by 109333.33% in 2022 and then crashed by 7922.08% in 2023.
  • Viridian Therapeutics, Inc.\DE's Capital Expenditures (Quarter) stood at $84000.0 in 2021, then surged by 175.0% to $231000.0 in 2022, then tumbled by 79.22% to $48000.0 in 2023, then skyrocketed by 137.5% to $114000.0 in 2024, then grew by 11.4% to $127000.0 in 2025.
  • Its last three reported values are $127000.0 in Q3 2025, $42000.0 for Q2 2025, and $86000.0 during Q1 2025.